• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Exelon (rivastigmine tartrate)

Changes to Prescribing Information for Exelon. The changes provide guidelines for reinitiating therapy in patients who have interrupted treatment with Exelon, to reduce the risk of severe vomiting.

[January 31, 2001 - Letter - Novartis Pharmaceuticals]